Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2110MR)

This product GTTS-WQ2110MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2110MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ948MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-323
GTTS-WQ279MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ2366MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ11950MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ15726MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA VIR-7831
GTTS-WQ2879MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-761
GTTS-WQ14304MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ15922MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XOMA 052
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW